3 Things You Didn’t Know About bluebird bio, Inc. – Motley Fool
Motley Fool |
3 Things You Didn't Know About bluebird bio, Inc.
Motley Fool Most investors are rightfully focused on Bluebird's LentiGlobin gene therapy treatment. It offers nice potential in the orphan indication of beta thalassemia, plus a more lucrative indication in sickle-cell disease. But there's a gene–therapy product … |
